Literature DB >> 11442496

In vitro induction of apoptosis for nasal angiocentric natural killer cell lymphoma-derived cell line, NK-YS, by etoposide and cyclosporine A.

M Uno1, J Tsuchiyama, A Moriwaki, T Noguchi, K Mizoguchi, T Ogino, T Yoshino, S Okada, M Harada.   

Abstract

Epstein-Barr virus (EBV)-associated nasal T/natural killer (NK) cell lymphoma has often been reported in Asian countries and has been recently confirmed as a novel clinicopathological entity. The prognosis of advanced stage disease is quite poor and an effective chemotherapeutic modality is strongly advocated. We have established the novel cell line NK-YS, which preserves the original characteristics of EBV-associated nasal angiocentric T/NK cell lymphoma. Using this cell line, we investigated the induction of apoptosis by apoptosis-inducing agents, and expression of P-glycoprotein (P-gp), p53 and bcl-2 proteins. NK-YS showed resistance towards apoptosis-inducing agents and expressed bcl-2 and P-gp but not p53. To overcome this drug resistance, we added cyclosporine A (CsA) and these agents to culture media as a P-gp antagonist. The combination of CsA and etoposide or CsA and doxorubicin induced apoptotic cell death. These results indicated that P-gp-mediated drug resistance is an essential mechanism of drug resistance of the NK-YS cell line. Combined therapy of conventional anti-cancer agents with CsA may have an important place in the establishment of a curative therapy for disseminated nasal angiocentric NK cell lymphoma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11442496     DOI: 10.1046/j.1365-2141.2001.02844.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

1.  Novel therapies for peripheral T-cell lymphomas.

Authors:  Andrei Shustov
Journal:  Ther Adv Hematol       Date:  2013-06

Review 2.  Treatment of localized extranodal NK/T cell lymphoma, nasal type.

Authors:  Seok Jin Kim; Won Seog Kim
Journal:  Int J Hematol       Date:  2010-11-18       Impact factor: 2.490

3.  Risk of etoposide-related acute myeloid leukemia in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.

Authors:  Shinsaku Imashuku; Tomoko Teramura; Kikuko Kuriyama; Junichi Kitazawa; Etsuro Ito; Akira Morimoto; Shigeyoshi Hibi
Journal:  Int J Hematol       Date:  2002-02       Impact factor: 2.490

4.  Retrospective study of modified SMILE chemotherapy for advanced-stage, relapsed, or refractory extranodal natural killer (NK)/T cell lymphoma, nasal type.

Authors:  Li Yang; Hong Liu; Xiao-hong Xu; Xin-feng Wang; Hong-ming Huang; Wen-yu Shi; Sheng-hua Jiang
Journal:  Med Oncol       Date:  2013-09-24       Impact factor: 3.064

5.  Treatment of Aggressive NK-Cell Leukemia: A Case Report and Review of the Literature.

Authors:  Anders Kindberg Boysen; Paw Jensen; Preben Johansen; Karen Dybkær; Mette Nyegaard
Journal:  Case Rep Hematol       Date:  2011-11-21

6.  Treatment of localized extranodal NK/T cell lymphoma, nasal type: a systematic review.

Authors:  Seok Jin Kim; Sang Eun Yoon; Won Seog Kim
Journal:  J Hematol Oncol       Date:  2018-12-20       Impact factor: 17.388

7.  One method to establish Epstein-Barr virus-associated NK/T cell lymphoma mouse models.

Authors:  Weili Xue; Weiming Li; Yufeng Shang; Yanjie Zhang; Xuan Lan; Guannan Wang; Zhaoming Li; Xudong Zhang; Yue Song; Baopeng Wu; Meng Dong; Xinhua Wang; Mingzhi Zhang
Journal:  J Cell Mol Med       Date:  2018-11-28       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.